6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
申请人:Pfizer Inc.
公开号:US04432970A1
公开(公告)日:1984-02-21
6-beta-Halopenicillanic acid 1,1-dioxides, physiologically acceptable salts thereof and esters thereof readily hydrolyzable; pharmaceutical compositions containing a 6-beta-halopenicillanic acid 1,1-dioxide, a physiologically acceptable salt thereof or an ester thereof readily hydrolyzable; and a method for enhancing the effectiveness of a beta-lactam antibiotic, using a 6-beta-halopenicillanic acid 1,1-dioxide, a physiologically acceptable salt thereof or an ester thereof readily hydrolyzable.
[EN] REACTIONS OF STANNYL CATIONS<br/>[FR] RÉACTIONS DE CATIONS STANNYLE
申请人:IMPERIAL INNOVATIONS LTD
公开号:WO2017212289A1
公开(公告)日:2017-12-14
The present invention relates to a method of reducing, cleaving and/or coupling at least one C=O, C-O, C=C or C=N bond of a compound, using a reagent comprising a stannyl cation.
refluxing THF resulted in the oxidative addition of the inactive R3Sn–C bond to the tungsten atom to yield metal-metal bonded complexes CH2CH(3,5-Me2Pz)2W(CO)3SnR3. While reaction of R3SnCH2CH(mim)2 (R = n-Bu or Ph; mim = 1-methylimidazol-2-yl) with W(CO)6 in refluxing dioxane gave only the decarbonylation complexes R3SnCH2CH(mim)2W(CO)4, no analogous oxidative addition of the R3Sn–C bond was observed
The proton magnetic resonance spectra of benzyltin derivatives
作者:L. Verdonck、G.P. Van Der Kelen
DOI:10.1016/s0022-328x(00)85156-6
日期:1966.6
The PMR spectra of a series of benzyltin compounds (C6H5CH2)nSnX4-n (I⪡n⪡4, X=H, Cl, Br, I, OCOCH3) have been studied. Evidence is presented that substituents X equally influence all the ring protons chemical shifts and this is ascribed to changes in the π-electron system of the ring. The methylene group shifts are the result of ring current, inductive effect and diamagnetic anisotropy contributions
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.